Category: amcenestrant

  • Roche’s oral SERD giredestrant fails breast cancer trial

    Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the emerging oral selective oestrogen receptor degrader (SERD) class. The Swiss pharma said in its update that the acelERA trial comparing giredestrant to physician’s choice […]

  • Sanofi takes a hit as hotly tipped breast cancer drug fails trial

    Shares in Sanofi were on the slide this morning after the drugmaker revealed that one of its top pipeline prospects – selective oestrogen receptor degrader (SERD) amcenestrant – stumbled in a mid-stage breast cancer trial. The phase 2 AMEERA-3 trial was testing amcenestrant in women aged 18 and over with hormone receptor-positive, HER2-negative advanced breast […]